Paper Title
Digistain: A Novel, Rapid & Cost Effective Prognostic Marker for Guiding Adjuvant Therapy in Er+, Her2- Breast Cancer

Abstract
Current guidelines suggest a companion diagnostic be used to evaluate the recurrence risk of ER+, HER2- breast tumours in order to mitigate the overuse of broad-spectrum chemotherapy which results in chemo-related toxicity responsible for significantly elevated risk of cardiovascular failure. These diagnostic tests however are prohibitively expensive for most patients in the developing world meaning only a tiny fraction of eligible patients receive such diagnoses resulting in the systemic overuse of chemotherapy. We report on the utility of Digistain - a new prognostic marker for HER2-, ER+ breast tumours with upto 3 positive lymph nodes that is extremely cost effective and which rapidly (<1 hour) reports on the risk of 10 year recurrence in breast cancer Digistain’s proprietary algorithm translates information on tumour chemical composition into a quantitative ‘score’ that predicts the proliferation risk of sample cancer cells. The technology captures a unique spectral signature from each biopsy and performs an analysis on 10,000 data points to produce a risk score. Digistain’s technique is designed to be applied on available tumour samples and prepared using standard processing, making it immediately compatible with current hospital diagnostic workflows.